Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BKT170
- Development stage
- Preclinical
- Lead developer
- Biokine Therapeutics
- Modality
- Peptides, Small Molecules
- Administration
- Topical
01
Overview
BKT170 is a preclinical drug candidate developed by Biokine Therapeutics, specifically designed to target the C-X-C Motif Chemokine Receptor 4 (CXCR4). As a CXCR4 antagonist, BKT170 is being explored for its potential in treating various skin conditions, likely by modulating the inflammatory and immune cell migration pathways mediated by the CXCR4/CXCL12 axis. Biokine Therapeutics focuses on developing CXCR4-targeted therapies, and BKT170 represents an expansion of their pipeline into dermatological indications. The drug is intended to address pathological processes in the skin where CXCR4 signaling plays a critical role in disease progression.
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on BKT170.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BKT170.